Megan Thomas explores the innovation and opportunity for cancer vaccines with Dr Alexander Zehnder, CEO of CureVac, and Dr Chris Haqq, Chief Medical Officer of Elicio Therapeutics. It could be argued that Covid-19 gave us a boost to start making headway in cancer vaccines. Between the acceleration of mRNA vaccine technology, increased investment, a case […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!